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Abstract
Insulin concentrations in humans continuously change and
typically increase only when glucose also increases such as
with eating. In this setting, it is not known whether the
severity of hepatic and extrahepatic insulin resistance is
comparable and whether the ability of glucose to regulate
its own uptake and release is defective in non-insulin-de-
pendent diabetes mellitus (NIDDM). To address this ques-
tion, NIDDM and nondiabetic subjects were studied when
glucose concentrations were clamped at either 5 mM (eugly-
cemia) or varied so as to mimic the glucose concentrations
observed in nondiabetic humans after food ingestion (hyper-
glycemia). Insulin was infused so as to simulate a "nondia-
betic" postprandial profile. During euglycemia, insulin in-
creased glucose disposal in nondiabetic but not diabetic sub-
jects indicating marked extrahepatic resistance. In contrast,
insulin-induced suppression of glucose release was only min-
imally less (P < 0.05) in diabetic than nondiabetic subjects
(-1.06±0.09 vs. -1.47±0.21 nmol kg-l per 4 h). Hypergly-
cemia substantially enhanced disposal in both groups. Glu-
cose effectiveness measured as the magnitude of enhance-
ment of disposal (0.59±0.18 vs. 0.62±0.17 nmol kg-l per 4
h) and suppression of release (-0.36±0.12 vs. -0.14±0.12
nmol kg-l per 4 h) did not differ in the diabetic and nondia-
betic subjects. In conclusion, when assessed in the presence
of a physiological insulin profile, people with NIDDM dem-
onstrate: (a) profound extrahepatic insulin resistance, (b)
modest hepatic insulin resistance, and (c) normal ability of
glucose to stimulate its own uptake and suppress its own
release. (J. Clin. Invest. 1994. 94:2341-2348.) Key words:
insulin action * glucose effectiveness * glucose disposal
hepatic glucose release * diabetes mellitus
Introduction
Non-insulin-dependent diabetes mellitus (NIDDM)' is charac-
terized by defects in insulin secretion and action (1-7). The
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relative contribution of these defects to the excessive postpran-
dial hepatic glucose release and the inappropriately low glucose
uptake that is characteristic ofNIDDM is not known. Numerous
studies have suggested that insulin-induced suppression of he-
patic glucose release and stimulation of glucose disappearance
are impaired in NIDDM (2-7). Most of these studies have
obtained this information by using either hyperinsulinemic or
hyperglycemic clamps to evaluate steady state glucose metabo-
lism in the presence of constant glucose and insulin concentra-
tions (2-7). However, recent studies have demonstrated that
changing insulin concentrations have greater effects on glucose
metabolism than constant insulin concentrations (8-10). Fur-
thermore, under the conditions of daily living, insulin rarely if
ever increases without a concurrent increase in glucose (1).
This increase in plasma glucose may facilitate insulin-induced
suppression of hepatic glucose release ( 11-13 ) and stimulation
of tissue glucose uptake ( 15, 16). However, because the effects
of glucose on its own metabolism varies depending on the pre-
vailing insulin concentration, it is difficult to determine from
conventional hyperglycemic and/or hyperinsulinemic clamps
the extent to which the postprandial rise in glucose can compen-
sate for a decrease in insulin action.
The current studies therefore were undertaken to determine
whether in the presence of continuously changing insulin and
glucose concentrations the severity of hepatic and extrahepatic
insulin resistance were comparable and whether the effective-
ness of glucose per se was impaired in patients with NIDDM.
To examine this question, insulin action was assessed in diabetic
and nondiabetic subjects in the presence of insulin concentra-
tions that mimic those typically observed in healthy nondiabetic
subjects after carbohydrate ingestion (17). Glucose concentra-
tions either were maintained constant at euglycemic levels so
as to measure the effects of insulin per se or were varied to
simulate postprandial glucose concentrations so as to measure
the combined effects of glucose and insulin. The difference
between rates of glucose disposal and release observed during
the euglycemic and hyperglycemic experiments was used to
determine the extent to which glucose per se modulated its own
metabolism.
Methods
Subjects. After approval by the Mayo Institutional Review Board, 11
subjects with NIDDM and 10 nondiabetic subjects gave informed writ-
ten consent to participate in the study. Subjects were matched for the
characteristics listed in Table I including age, gender, and obesity. The
duration of diabetes was 5.1±1.1 yr (mean±SEM) at the time of study.
Seven patients were treated with sulfonylureas and four with diet alone.
Sulfonylurea treatment was discontinued 3 wk before study. All subjects
were in good health, had normal blood pressure, and were at stable
weight. None regularly engaged in vigorous aerobic exercise or were
taking any medications other than sulfonylureas. The nondiabetic sub-
jects did not have a family history of diabetes.
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Table L Subject Characteristics
Nondiabetic NIDDM
subjects subjects
Number 10 11
Sex (male/female) 5/5 8/3
Age (y) 55±2 54±2.3
Body mass index (kg/M2) 28.4±1 2.9±1.0
Waist-hip ratio 0.90±0.02 0.94±0.02
Body fat (%) 34±3.0 32±3
Fasting plasma glucose (mM) 5.3±0.05 12.4±1.2*
Glycosylated HbA,(%) 10.3±0.8
* P < 0.0001 vs. control subjects.
Experimental design. Subjects were admitted to the Clinical Re-
search Center at 1700 hour on the evening before study. A standard
meal (636 kcal; 48% carbohydrate, 32% fat, 19% protein) was eaten
between 1730 and 1800 hours after which subjects were fasted until the
end of the study. A 18-gauge catheter was inserted into a vein of each
forearm on the evening of admission. One was connected to a multiport
infusion set (Burro Medical Inc., Bethlehem, PA) and used for all study
infusions. The other cannula was used overnight for blood sampling.
At the time of meal ingestion an infusion of 0.9% saline (nondiabetic)
or insulin (1 U/10 ml of saline containing albumin) was started. The
insulin infusion was adjusted according to the algorithm of White et al.
(18) to maintain nocturnal glucose concentrations in the diabetic sub-
jects at concentrations of - 5 mM. On the following morning the venous
sampling cannula was removed and a cannula was placed retrogradely
into a dorsal hand vein, which was inserted into a heated plexiglass box
and maintained at 55°C to allow intermittent sampling of arterialized
venous blood. An additional cannula was placed retrogradely into an
antecubital vein of the contralateral forearm to allow intermittent sam-
pling of deep venous blood.
At 0700 hours the next morning, infusions of somatostatin (2.2 ,4g/
m2 per minute), growth hormone (1 15 ng/m2 per min), and glucagon
(25 ng/m2 per minute) were started in both groups. An insulin infusion
also was started in the nondiabetic subjects. Plasma glucose determina-
tions were performed at 5-min intervals using a glucose oxidase method
(Yellow Springs Instrument Co., Yellow Springs, OH) and the insulin
infusion was adjusted in both groups to maintain glucose at - 5 mM,
until 1030 hours when the rate was fixed at a constant rate for the
remainder of the study. A primed-continuous infusion of [6-14C] glucose
(3 iCi prime, 0.03 4Ci/min continuous) was started at 0900 hours. [6-
3H]Glucose also was infused as part of a separate protocol. An addi-
tional insulin infusion was started at 1100 h in all studies. As previously
described (19), this so-called prandial insulin infusion was given by a
programmable infusion pump (model 22; Harvard Apparatus, South
Natick, MA) regulated by an on-line computer (PS2/30 265; Interna-
tional Business Machines, Rochester, MN). The infusion rate was
changed every 10 s so as to deliver insulin in a pattern that mimicked
the postprandial insulin concentrations previously observed in healthy
nondiabetic subjects (17). The prandial insulin infusion resulted in the
delivery of 1.01±0.01 U/M2 body surface area (or - 2 U per study).
Sufficient glucose was infused to maintain euglycemia on one occa-
sion while on a second occasion a "prandial" glucose profile was
mimicked as previously described (19). To maintain glucose specific
activity constant, all infused glucose contained [6-14C] glucose (20).
As previously discussed (7), the rate of the basal [6- '4C] glucose infu-
sion was adjusted (-120-0 min, 100%; 0-15 min, 70%; 15-75 min,
30%; 75-120 min, 60%; 120-240 min, 80% of basal) in an attempt to
reproduce the anticipated pattern of change of hepatic glucose release
to minimize changes in plasma glucose specific activity. The order of
study was random. Euglycemic studies were performed in all subjects;
nine nondiabetic and eight diabetic subjects also participated in the
hyperglycemic studies.
Analytical techniques. Arterialized plasma samples were placed on
ice, centrifuged at 4°C, separated, and stored at -20°C until assay.
Plasma insulin, C-peptide, glucagon, growth hormone, and glucose spe-
cific activity were measured as previously described (21, 22). Body fat
composition was determined by dual-energy x-ray absorptiometry (DPX
scanner; Lunar Corporation, Madison, WI). Glycosylated hemoglobin
concentration was measured by affinity chromatography (Gly-Affin;
Isolab, Akron, OH; normal range, 4-7%).
Calculations. Glucose specific activity was smoothed using the
method of Bradley et al. (23). Glucose appearance and disappearance
were calculated using Radziuk et al.'s two-compartment model (24).
Transfer constants in the basal state were estimated by nonlinear least
squares (25) using the data obtained after the priming dose of [6-
'4C]glucose. Hepatic glucose release was calculated by subtracting the
glucose infusion rate from the tracer determined rate of glucose appear-
ance. Arterial-venous (A-V) difference was calculated by subtracting
the glucose concentration present in deep venous blood from that present
in simultaneously obtained arterialized blood. Because forearm blood
flow did not differ before and after the prandial insulin infusion in
the diabetic or nondiabetic subjects on either the euglycemic (diabetic,
3.49±0.29 vs. 3.39+0.27; nondiabetic, 2.01±0.32 vs. 1.97±0.33 ml/
100 ml forearm) or hyperglycemic (diabetic, 2.71±0.37 vs. 2.6±0.40;
nondiabetic, 2.43±0.27 vs. 2.28±0.39 ml/ 100 ml forearm) study days
and because there was considerable intraindividual variability in blood
flow during the experiment, data are presented in the text and figures
as A-V glucose difference rather than forearm glucose uptake. Glucose
effectiveness was calculated by subtracting the results observed during
euglycemia in each individual from those observed in the same individ-
ual during hyperglycemia.
Statistical analysis. Data in text and figures are expressed as the
mean±SEM. Total integrated responses and responses above basal were
calculated using the trapezoidal rule. Total integrated response was de-
fined as total area above zero during the prandial insulin infusion. Area
above basal was defined as the area above the mean of the values present
during the 30 min before the prandial insulin infusion. Results between
groups (diabetic vs. nondiabetic) and within a group (hyperglycemic
vs. euglycemic) were compared using nonpaired and paired Student's
t test, respectively. One-tailed tests were used to test the hypotheses
that hepatic glucose release was greater and that glucose disposal was
lower. All other tests were two tailed. P < 0.05 was considered statisti-
cally significant.
Results
Glucose and insulin concentrations. Glucose concentrations did
not differ in the diabetic and nondiabetic subjects during the
basal period (i.e., during the 30 min before the prandial insulin
infusion) of either the euglycemic or hyperglycemic studies
(Fig. 1). During the prandial insulin infusions, glucose concen-
trations in both groups were either maintained constant (- 5
mM) or varied so as to mimic a postprandial rise in glucose
(1, 17). Glucose concentrations did not differ in the diabetic
and nondiabetic subjects during either prandial insulin infusion.
The insulin concentrations present during the basal period
were slightly but not significantly higher in the diabetic than
nondiabetic subjects during both the euglycemic (126±18 vs.
87±8 pmol/liter) and hyperglycemic (124+28 vs. 88±12
pmol/liter) studies. The increment above basal during the pran-
dial insulin infusion was the same in the diabetic and nondia-
betic subjects during both the euglycemic (8.8+0.9 vs. 8.7±+1.3
nmol/liter per 4 h) and hyperglycemic (9.6±1.2 vs. 8.3+0.9
nmol/liter per 4 h) studies.
C-peptide, glucagon, and growth hormone concentrations.
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Figure 1. Plasma glucose and insulin concentrations observed during
the euglycemic (left) and hyperglycemic (right) studies in the diabetic
and nondiabetic subjects. The prandial insulin infusion was started at
time 0.
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Figure 3. Glucose infusion rates required to achieve target glucose
concentrations and glucose specific activities observed in the diabetic
and nondiabetic subjects during the euglycemic (left) and hyperglyce-
mic (right) studies. The prandial insulin infusion was started at time 0.
C-peptide, glucagon, and growth hormone concentrations did
not differ in the diabetic and nondiabetic subjects on either the
euglycemic or hyperglycemic study days (Fig. 2).
Rates ofglucose infusion and glucose specific activity. The
glucose infusion rates required to maintain euglycemia
(0.87±0.11 vs. 1.94±0.19 mmol kg- per 4 h) or to reproduce
the prandial glucose profile (1.70±0.26 vs. 2.70±0.28
mmol -kg - per 4 h) were lower (P < 0.02) in the diabetic
than nondiabetic subjects, respectively (Fig. 3). Plasma glucose
specific activity increased sightly but comparably in both groups
during both studies.
Glucose disappearance and forearm A-V glucose differ-
ence. During the euglycemic study, whereas the prandial insulin
infusion caused a substantial increase in both glucose disappear-
ance and A-V difference in the nondiabetic subjects, it had no
effect on either of these parameters in the diabetic subjects (Fig.
4, left). Glucose disappearance was lower (P < 0.05) in the
diabetic than nondiabetic subjects during the prandial insulin
infusion whether expressed as the increase above basal
(-0.18+0.09 vs. 0.49±0.24 mmol kg-' per 4 h) or as the
total response (2.19±0.14 vs. 3.08±0.23 mmol kg-' per 4 h).
os
a 025
E
200-
L
E 4
Euglycemiia Hyperglycemia
05
C-Peptide
0 Nordoabetc - 025 40
Diabetic E
Glucagon 200
GL
_ O
Growth Hormone a
0 120 240
Time (min)
3a
0~~
~~
12 24
Time (min)
Similarly the increase in A-V glucose difference was lower
(P < 0.01) in the diabetic than nondiabetic subjects whether
expressed as the increase above basal (-9±14 vs. 78±15
mmol/liter per 4 h) or the total response (33±+11 vs. 125±21
mmol/liter per 4 h).
During the hyperglycemic study, the prandial insulin infu-
sion resulted in a substantial increase in glucose disappearance
and A-V glucose difference in both groups (Fig. 4, right).
However, both glucose disappearance (area above basal,
0.36±0.26 vs. 0.97+0.18 mmol kg-' per 4 h; total response,
2.73±0.21 vs. 3.69±0.32 nmol kg -per4 h) and A-V glucose
difference (area above basal, 33±11 vs. 93±21 mmol/liter per
4 h; total response, 86±19 vs. 178±43 mmol/liter per 4 h)
remained lower (P < 0.05) in the diabetic than nondiabetic
subjects.
Hepatic glucose release. Consistent with the higher basal
insulin concentrations, basal rates of hepatic glucose release
were slightly but not significantly lower in the diabetic than
nondiabetic subjects during both the euglycemic (9.9±0.5 vs.
10.8±0.9 pmol kg-'/minute, P = 0.37) and the hyperglycemic
(9.8±0.7 vs. 11.3±0.8 ttmol kg- per minute, P = 0.16) stud-
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Figure 2. Plasma C-peptide, glucagon, and growth hormone concentra-
tions observed in the diabetic and nondiabetic subjects during the eugly-
cemic (left) and hyperglycemic (right) studies. The prandial insulin
infusion was started at time 0.
Figure 4. Rates of glucose disappearance and forearm A-V difference
observed in the diabetic and nondiabetic subjects during the euglycemic
(left) and hyperglycemic (right) studies. The prandial insulin infusion
was started at time 0.
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Figure 5. Rates of hepatic glucose release observed in the diabetic and
nondiabetic subjects during the euglycemic (left) and hyperglycemic
(right) studies. The prandial insulin infusion was started at time 0.
ies (Fig. 5). Although the prandial insulin infusion resulted in
prompt suppression of hepatic glucose release in both groups
on both occasions, the degree of suppression was less (P
< 0.05) in the diabetic than nondiabetic subjects during the
euglycemic (-1.06±0.09 vs. -1.47+0.21 nmol kg-I per 4 h)
and the hyperglycemic (-1.34+0.16 vs. -1.76±0.14
nmol kg-l per 4 h) experiments. Because the increment in
insulin concentrations was the same in both groups, this indi-
cated the presence of insulin resistance.
The effect of glucose per se on glucose disappearance and
hepatic glucose release. To examine the effects of glucose per
se on glucose disappearance and hepatic glucose release, results
in the eight diabetic and nine nondiabetic subjects who under-
went both hyperglycemic and euglycemic studies were ana-
lyzed. Although glucose concentrations by design differed, as
is evident from Fig. 1, insulin concentrations were virtually
identical during the hyperglycemic and euglycemic experiments
in both the diabetic and nondiabetic subjects. C-peptide, gluca-
gon, and growth hormone concentrations also were the same
during both studies in both groups.
Hyperglycemia substantially increased glucose disappear-
ance and forearm A-V glucose difference in the diabetic and
nondiabetic subjects (see Fig. 6, left and middle). Although
hyperglycemia also enhanced suppression of hepatic glucose
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Figure 6. Rates of glucose disappearance, forearm A-V difference, and
hepatic glucose release observed in the diabetic (top) and nondiabetic
subjects (bottom) during the euglycemic (open circles) and hyperglyce-
mic (solid squares) studies. The prandial insulin infusion was started
at time 0.
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Figure 7. The effects of glucose per se on glucose disappearance (left),
forearm A-V glucose difference (middle), and hepatic glucose release
(right) were determined by subtracting the rates observed in each indi-
vidual during the euglycemic from those observed in the same individual
during the hyperglycemic studies. Results observed in the diabetic sub-
jects are shown as open bars and results observed in the nondiabetic
subjects are shown as closed bars.
release, this effect was relatively small in both groups (Fig. 7,
right). To determine whether the ability of glucose to facilitate
its own uptake and suppress it own release was impaired in
NIDDM, the increment above basal during euglycemia in each
individual was subtracted from that observed in the same indi-
vidual during hyperglycemia. As shown in Fig. 7, the ability of
glucose to stimulate glucose disposal did not differ in the dia-
betic and nondiabetic subjects whether measured isotopically,
as glucose disappearance (0.59+0.18 vs. 0.62±0.17 nmol-kg-'
per 4 h) or as forearm A-V glucose difference (51+20 vs.
65±+33 mmol/liter per 4 h). In addition, the ability of glucose
to inhibit hepatic glucose release if anything was slightly greater
in the diabetic than nondiabetic subjects (-0.36+0.13 vs.
-0.14+0.1 1 nmol -kg -' per 4 h).
Discussion
Both glucose and insulin regulate hepatic and muscle glucose
metabolism (11-16). Whereas numerous studies have demon-
strated that people with NIDDM are insulin resistant, the contri-
bution of insulin resistance to carbohydrate intolerance under
physiological conditions remains uncertain. Furthermore, be-
cause the ability of glucose per se to inhibit glucose production
and to stimulate glucose utilization is dependent upon the pre-
vailing insulin concentrations ( 11-16), the extent to which the
response to increasing glucose concentrations either compen-
sates for or exacerbates insulin resistance in people with
NIDDM is unknown. The present studies indicate that small
amounts of insulin (- 2 U), when given so as to mimic normal
postprandial systemic insulin concentrations, have surprisingly
potent effects on glucose metabolism. They result in prompt
suppression of hepatic glucose release in both diabetic and non-
diabetic subjects. In contrast, whereas insulin administered in
this manner produces a brisk increase in glucose disposal in
nondiabetic individuals, it has virtually no effect on glucose
disposal in people with NIDDM. However, an increase in glu-
cose concentration similar to that observed in nondiabetic sub-
jects after ingestion of 50 g of carbohydrate markedly and com-
parably enhances glucose disposal in both groups. Although
hyperglycemia only minimally further suppresses hepatic glu-
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cose release, the magnitude of this effect also was the same in
the diabetic and nondiabetic subjects. These data indicate that
although people with NIDDM are resistant to the effects of
insulin, they are not resistant to the regulatory effects of glucose.
These data also indicate that in the presence of physiological
changes in insulin concentrations, there is a marked difference
in the severity of hepatic and extrahepatic insulin resistance in
NIDDM.
The effects of insulin on glucose metabolism in NIDDM. A
variety of techniques have been used to assess insulin action in
people with NIDDM (26). The hyperinsulinemic euglycemic
clamp is perhaps the most widely used. When submaximal insu-
lin concentrations are used, this method has shown repeatedly
that people with NIDDM have both hepatic and extrahepatic
insulin resistance (3-7). Although this method permits the re-
sponse to a given insulin concentration to be quantitated, it
necessitates maintenance of insulin concentrations constant for
several hours, a circumstance rarely if ever observed under
physiological conditions. We and others have shown that the
response to insulin is greater when insulin is administered so
as to produce changing rather than constant insulin concentra-
tions (8-10). An enhanced response to changing insulin con-
centrations may account at least in part for the near normal
pattern of suppression of hepatic glucose release observed in
the diabetic subjects. It is possible that the overnight insulin
infusion improved hepatic insulin action in the diabetic subjects.
However, it did not normalize insulin action because the decre-
ment in hepatic glucose release in response to the same incre-
ment in insulin was slightly (but significantly) less in the dia-
betic than nondiabetic subjects. In addition, we have demon-
strated in a separate series of experiments that hepatic glucose
release during a traditional hyperinsulinemic euglycemic clamp
remains excessive after an overnight insulin infusion (26a).
Finally, even if the nocturnal infusion improved hepatic insulin
action, it clearly did not restore the extrahepatic response to
insulin.
The marked disparity between the degree of hepatic and
extrahepatic insulin resistance is intriguing. Recent studies have
demonstrated that insulin must traverse an endothelial barrier
to reach the interstitial fluid that bathes muscle (27). In contrast,
insulin presumably has ready access to the liver via the large
fenestrations present in the portal venous system (28). How-
ever, the difference in the hepatic and extrahepatic response to
insulin in the diabetic subjects is unlikely to be solely due
to slowed equilibration between blood and interstitial insulin
concentrations because this presumably would be associated
with a delayed rather than a virtually absent response to insulin.
Alternatively the discordance between the severity of hepatic
and extrahepatic insulin resistance may be due to differences
in liver and muscle insulin binding and/or signal transduction
(29-31 ). Insulin increases glucose uptake in muscle primarily
by increasing the translocation of glucose transporters to the
plasma membrane whereas it decreases hepatic glucose release
by altering the activity of glycogenolytic and gluconeogenic
enzymes (13, 32). Therefore, a defect in a signaling pathway
(e.g., glucose transport) present in muscle but not in the liver
could readily explain the present results.
Regardless of the mechanism(s), the near normal suppres-
sion of hepatic glucose release by insulin in the diabetic subjects
in the face of virtually no change in glucose disposal is of
considerable interest in view of recent data from nondiabetic
animals that suggest a causal relationship between these two
processes (33, 34). If insulin's effects on liver and muscle
glucose metabolism indeed are mediated through a single rate-
limiting step in nondiabetic humans, this relationship clearly is
altered in people with NIDDM.
The effects of glucose per se on glucose metabolism in
NIDDM. In previous studies in a separate group of subjects, we
have demonstrated that the same glucose and insulin profiles
as used in the hyperglycemic portion of the present experiments
resulted in normal suppression of hepatic glucose release and
substantial, albeit not fully normal, stimulation of glucose up-
take in people with NIDDM (19). The present experiments
confirm these observations. However, because both glucose and
insulin increased concurrently in our previous experiments, we
could not distinguish abnormalities due to alterations in insulin
action from those due to alterations in the effectiveness of glu-
cose. This question was addressed in the present experiments
by studying the same individuals twice under identical condi-
tions with the exception that on one occasion euglycemia was
maintained whereas on the other occasion a postprandial glu-
cose profile was produced. Whereas the insulin infusion had
essentially no effect on glucose disposal in the diabetic subjects
when euglycemia was maintained, in the presence of hypergly-
cemia it resulted in an increase in glucose disposal to rates
similar to those observed in the nondiabetic subjects during
insulin alone (Fig. 4). In contrast, insulin had a marked inhibi-
tory effect on hepatic glucose release in both groups with sup-
pression being only modestly enhanced by hyperglycemia. Of
perhaps greatest interest, despite the marked differences in insu-
lin action, the effectiveness of glucose, calculated by subtracting
the results observed during the euglycemic experiments from
those observed during the hyperglycemic experiments, did not
differ in the diabetic and nondiabetic subjects (Fig. 7).
Previous investigations of glucose effectiveness in NIDDM
have yielded results that at first glance appear to be contradic-
tory (35-37). Capaldo et al. (35) reported that glucose effec-
tiveness in the presence of insulin deficiency is normal whereas
Baron et al. (36) reported that it is increased. On the other
hand, Welch et al. (37) reported that glucose effectiveness in
the presence of basal insulin concentrations is decreased. These
apparent inconsistencies likely are due to the fact each investi-
gator used a different strategy to try to factor out the effects of
glucose from those of insulin.
It should be noted that the definition and measurement of
glucose effectiveness used in the present study is different from,
albeit related to, that used by these investigators (26, 35-37).
First, we have examined both hepatic and peripheral glucose
effectiveness. Hepatic glucose effectiveness is defined in this
study as the difference between hepatic glucose release ob-
served during the hyperglycemic and euglycemic experiments.
Peripheral glucose effectiveness is defined as the difference
between glucose disposal or forearm A-V glucose extraction
during the hyperglycemic and euglycemic experiments. Second,
and perhaps more importantly, glucose effectiveness in the pres-
ent experiments was measured under nonsteady state conditions
during a prandial insulin profile. Because insulin is continuously
changing in the present study, each index of glucose effective-
ness (hepatic/extrahepatic) does not refer to a single fixed level
of insulin (26, 35-37). This distinction is important because
in the presence of basal insulin concentrations non-insulin-
dependent tissues (e.g., gut, brain) account for the majority of
glucose disposal. In contrast, during a prandial rise in insulin,
the majority of glucose is taken up by insulin-sensitive tissues
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(e.g., muscle). In addition, previous investigations have shown
that the effect of glucose on its own disposal in both nondiabetic
humans and people with type 1 diabetes mellitus is dependent
on insulin (14-16); an increment in glucose concentration re-
sults in a greater increment in glucose disposal when insulin
concentrations are high than when insulin concentrations are
low (14-16). Under normal living conditions, an increase in
glucose concentrations in nondiabetic individuals is invariably
accompanied by a concomitant increase in insulin. The present
experimental design was therefore chosen in an effort to gain
insight into the interaction between glucose and insulin under
physiological conditions.
If insulin indeed modulates glucose effectiveness, how then
can insulin facilitation of glucose effectiveness be normal in
NIDDM when the ability of insulin to stimulate glucose uptake
at any given glucose concentration is impaired? Glucose effec-
tiveness in peripheral tissues represents the ability of glucose
to enhance its own disappearance at a given level of insulin.
Insulin sensitivity can be viewed as the ability of insulin to
enhance glucose effectiveness at a given glucose concentration.
In non-steady state, such as in the present experiments, glucose
effectiveness represents the sum of at least two components:
one is the glucose effectiveness at basal insulin concentrations
and the other is the enhancement of glucose effectiveness due
to insulin action. When both glucose and insulin concentrations
are changing, the sum of these two components is time varying.
Our measure of glucose effectiveness is related to the integral
of this time-varying glucose effectiveness. The finding that dia-
betic subjects have normal glucose effectiveness despite marked
insulin resistance indicates that the interaction between glucose
and insulin differs in the diabetic and nondiabetic subjects.
These data imply that hyperglycemia in some way compensates
for the inability of insulin to stimulate glucose uptake. This
postulated effect of hyperglycemia per se might occur either
independently from insulin or synergistically with insulin. The
hypothesis of a compensatory effect of hyperglycemia in
NIDDM is in good agreement with the results previously re-
ported by Revers et al. (38) derived during hyperinsulinemic
euglycemic and hyperglycemic glucose clamps.
Glucose effectiveness could compensate for insulin resis-
tance via several mechanisms. First, glucose effectiveness at
basal insulin concentrations could be higher in diabetic than
nondiabetic subjects. This supposition is not supported by the
previous report by Welch et al. (37) that glucose effectiveness at
basal insulin concentrations is decreased rather than increased.
Second, hyperglycemia in itself could modulate glucose effec-
tiveness by enhancing intracellular enzyme activity (e.g., glyco-
gen synthase activity) (39, 40). However, an alteration in intra-
cellular glucose metabolism presumably would not influence
glucose uptake if glucose transport/phosphorylation remained
rate limiting. Data have been presented arguing both for (41,
42) and against (43) transport/phosphorylation as the rate-lim-
iting step for glucose uptake in NIDDM during insulin infusion.
Third, although transport may remain rate limiting, hyperglyce-
mia and hyperinsulinemia may facilitate glucose uptake via
different transporters. For example, whereas insulin may act by
increasing the number/activity of transporters with a low Km
(e.g., glut-4 transporters) for glucose (for review see reference
44), hyperglycemia may increase glucose uptake predominantly
via transporters with a higher Km (e.g., glut- I ) for glucose (45 ).
Fourth, hyperglycemia could increase the number or type of
transporters (46). If so, acute increases in glucose and insulin
must have different effects on these transporters. This postulate
is consistent with the recent report by Dimitrakoudis et al. (47)
that chronic hyperglycemia increases the number of glut-I but
not glut-4 transporters in muscle. If indeed hyperglycemia is
able to compensate for defects in insulin action, then multiple
factors could contribute to "glucose effectiveness." Future
studies will be required to determine the relative contribution
of each of these mechanisms to the preservation of normal
glucose effectiveness in NIDDM.
Limitations. It is impossible to prove that "glucose effec-
tiveness" in the presence of prandial insulin concentrations is
the same in diabetic and nondiabetic subjects. Using the current
experimental design, we have found no evidence that the ability
of glucose to facilitate its own uptake and to inhibit its own
release is impaired in NIDDM. Although it is possible that
methods used were not sufficiently sensitive to detect a true
difference, we doubt that this is the case for several reasons.
First, we could readily detect differences in insulin action be-
tween groups during both the euglycemic and hyperglycemic
experiments. Second, the conclusions were concordant whether
glucose effectiveness was assessed using the isotope dilution
or the forearm catheterization techniques. Although the forearm
data are reported as the A-V difference, expression as forearm
glucose uptake (i.e., multiplying the A-V difference by
'noisy" blood flows) yielded the identical conclusion. Third,
there was extensive overlap between the diabetic and nondia-
betic groups in the ability of glucose to enhance its own uptake;
the ability of glucose to inhibit its own release, if anything,
was greater in the diabetic than nondiabetic subjects. Therefore,
although it is possible that we failed to detect a true impairment
in glucose effectiveness in NIDDM, if so, the magnitude of
such a defect is likely small.
Measurement of glucose turnover during non-steady state
is problematic. Several recent studies have demonstrated that
nonsteady state errors can be avoided by preventing rapid
changes in glucose specific activity (20, 48, 49). Although
glucose specific activity increased slightly during the present
experiments, these slight changes in specific activity introduce
minimal or no error in measurement of tumover (20, 48, 49).
In addition, the pattem of change in specific activity was the
same in the diabetic and nondiabetic subjects.
An ovemight insulin infusion was used in the diabetic sub-
jects to ensure that the glucose concentrations were the same
in both groups before and during the prandial insulin infusions.
The effect, if any, of this ovemight insulin infusion on insulin
action currently is not known. Glucagon concentrations were
maintained constant and equal in both groups during all experi-
ments by infusing somatostatin and replacement amounts of
glucagon. This differs from the normal situation in which fasting
glucagon concentrations tend to be higher and in which suppres-
sion after carbohydrate ingestion tends to be lower in diabetic
than nondiabetic subjects (50, 51 ). Although the present experi-
ments indicate that the hepatic response to a "physiological"
insulin profile is only minimally impaired, inappropriately ele-
vated glucagon concentrations that are observed in diabetic peo-
ple after food ingestion may magnify this defect.
In contrast to what occurs after food ingestion, glucose and
insulin were infused into the peripheral rather than the portal
venous systems. Somatostatin infusion resulted in essentially
complete inhibition of insulin secretion in both groups of sub-
jects. Although the prandial insulin infusions were identical in
both groups, the absolute insulin levels were higher in the dia-
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betic subjects because of their higher basal insulin concentra-
tions (19, 52). On the other hand, the increment in systemic
and therefore presumably portal venous insulin concentrations
produced by the prandial insulin infusions was the same in
the diabetic and nondiabetic subjects. Although not directly
measured, we doubt that hepatic glucose uptake is impaired in
NIDDM because previous experiments examining splanchnic
glucose extraction after ingestion of radiolabeled meals found
no evidence for such a defect in either diabetic animals or
humans (21, 53, 54).
Summary and conclusions. The present experiment clearly
demonstrate a discordance between the severity of hepatic and
extrahepatic insulin resistance in people with NIDDM. Whereas
administration of insulin in a manner that produced continu-
ously changing insulin concentrations had no effect on glucose
disposal, it resulted in prompt suppression of hepatic glucose
release. In contrast, glucose disposal was markedly stimulated
when the increase in insulin was accompanied by an increase
in glucose concentration. Despite the presence of insulin resis-
tance in the diabetic subjects, the ability of glucose to facilitate
its own uptake and to suppress it own release was not impaired.
Thus, although restoration of insulin secretion in people with
NIDDM may be accompanied by a normal hepatic response,
extrahepatic carbohydrate metabolism is likely to remain abnor-
mal. These data also suggest that new therapies should be di-
rected primarily toward improvement of extrahepatic insulin
action rather than altering hepatic responsiveness to insulin or
glucose effectiveness. The mechanism that permits normal glu-
cose but abnormal insulin facilitation of glucose uptake in peo-
ple with NIDDM requires further investigation.
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